Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Leqvio siRNA Drug Substance Facility in by Year
Leqvio siRNA Drug Substance Facility in Schweizerhalle, Switzerland (m²)
Novartis Leqvio siRNA Drug Substance Facility in: 8,880 in FY2025, unchanged from a year earlier.
Latest, FY2025
8,880
Period ended Dec 31, 2025
Change on a year earlier
0.0%
8,880 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Schweizerhalle, Switzerland | 8 880 | Manufacture of small-interfering RNA (siRNA) drug substance for Leqvio”
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Item 4.D.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Leqvio siRNA Drug Substance Facility in Schweizerhalle, Switzerland (m²) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8,880 | 0.0% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 8,880 | 0.0% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2023 | Dec 31, 2023 | 8,880 | – | Novartis Form 20-F (0001370368-24-000004) ↗ |
Cite this data
StockData. (2026). Novartis Leqvio siRNA Drug Substance Facility in, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/fac-schweizerhalle-m2
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.